Non-Human Genomics Market is projected to reach a value of $28.25 Billion by 2030

According to the report published by Virtue Market Research, the Global Non-human genomics market was valued at $9.3 billion in 2022 and is projected to reach a market capitalization of $28.25 billion by 2030. Over the forecast period of 2023-2030, the market is estimated to grow at a CAGR of 14.9% from 2023 to 2030.

Read More @ https://virtuemarketresearch.com/report/global-non-human-genomics-market

The non-human genomics market refers to the analysis of genetic information from non-human organisms. This may include animals, plants, and microorganisms and involve the use of techniques such as genetic sequencing, bioinformatics, and others to understand their genetic makeup, characteristics, and functions. The non-human genomics market usually refers to the sub-segment of the biotechnology industry sector that focuses primarily on the study and analysis of genetic information. The non-human genomics market is likely to grow in the forthcoming years owing to increasing demand for sustainable agricultural practices, new drug development initiatives, conservation efforts, and scientific research programs initiated all over the world. It is increasingly being used in the agriculture sector to develop crops and livestock that are more resistant to pests, diseases, and environmental stresses. This is helping to improve the productivity of agricultural systems and reduce the use of harmful chemicals, driving demand for non-human genomics products and services. Additionally, the rapid advances in genomics, such as next-generation sequencing, genome editing, and bioinformatics, have made it easier and less expensive to study the genomes of non-human organisms. This has led to an increase in the number of applications for non-human genomics, driving the global non-human genomics market growth.

The COVID-19 pandemic has had a mixed impact on the non-human genomics market with some disruption in supply chains and laboratory operations. On the one hand, the pandemic has caused some delays in research and development activities, as well as disruptions in the distribution chains of key materials and reagents needed for genomics research. This has led to delays in some projects and a slowdown in some areas of the non-human genomics market. On the other hand, it has also created new opportunities for genomics technologies, particularly in the development of diagnostics, therapeutics, and vaccines for COVID-19. The genomics technologies used for COVID-19 research and development include next-generation sequencing, gene editing, and bioinformatics, among others. Additionally, it is increasingly being used in the development of new drugs and therapies for a variety of diseases and conditions. This presents a significant opportunity for growth in the pharmaceutical sector, as well as in the genomics market more broadly. Also, the increasing capital investments made by major companies in the pharmaceutical sector are further fueling research and development activities, opening up lucrative opportunities for new entrants and widening the scope of the global market. It is also presenting a new and vast pool of job opportunities for the youth in the sector. Furthermore, the adoption of next-generation sequencing NGS technologies is increasing rapidly in the non-human genomics market due to its ability to generate large volumes of genomic data at a lower cost. Thus, NGS technologies are being used in a variety of applications, such as gene expression analysis, genome sequencing, and transcriptome analysis, which is driving the growth of the non-human genomics market globally.

Request Sample Copy of this Report @ https://virtuemarketresearch.com/report/global-non-human-genomics-market/request-sample

Segmentation Analysis:
The global Non-Human Genomics Market segmentation includes:

By Applications:
• Gene Expression
• Non-human Breeding
• Genetic Trait Testing, and Genetic Disease Testing.

The study of gene variation and inheritance in domestic and wild non-human animals is known as non-human genetics. This segment covers a major portion of the total market revenue shares. It consists of physical genetic traits that are only inherited, such as coat colour, body type, facial form, and others, as well as gene expression in non-human animals and non-human mating. Non-human animals are used for genetic disease training, genetic characteristic testing, and DNA analysis. The demand for meat products around the world is anticipated to expand over the course of the forecast period, as is the consumption of non-human proteins, which is predicted to increase along with the urban population augmenting the segment growth of non-human breeding.

By Technology:
• Sequencing, PCR
• Nucleic Acid Extraction and Purification
• Microarray
• Other Technologies

The technological segments in the genomics market include sequencing, PCR, nucleic acid extraction and purification, microarray, and other technologies. In terms of revenue, the sequencing sector dominated the Non-Human Genomics market in 2022. The advantages of sequencing technologies, such as their speed, scalability, and ultra-high throughput, enable researchers to tackle a range of projects, including farming, breeding non-human animals, and human genomics.

Regional Analysis:
North America is one of the largest marketplaces for non-human genomics research, driven by the presence of important academic and research institutions as well as important biotechnology and pharmaceutical companies. The biggest market in this region is America. Moreover, Europe is also emerging as a significant market for non-human genomics research, with a significant concentration of university and research institutions, as well as biotechnology and pharmaceutical firms. The biggest markets in this area are Germany, France, and the United Kingdom. The market for non-human genomics research is expanding at the quickest rate in Asia Pacific, due to rising investments in the field, an increase in the number of biotechnology and pharmaceutical firms, and a sizable population with varied genetic backgrounds. The three major markets in this area are China, India, and Japan.

Customize the Full Report Based on Your Requirements @ https://virtuemarketresearch.com/report/global-non-human-genomics-market/customization

Latest Industry Developments:
• The use of CRISPR-Cas9 technology for gene editing in non-human organisms is rapidly increasing. Applications range from agricultural breeding to developing new therapies for genetic diseases in animals. In June 2021, several companies announced new developments in CRISPR-based gene editing, including the first successful CRISPR-edited cow in Brazil through a collaboration between Embrapa and a local college.

• The availability of high-throughput sequencing technologies has enabled the rapid and cost-effective sequencing of non-human genomes, leading to new insights into the genetics of a wide range of organisms. In September 2021, significant progress was made in sequencing the genomes of several non-human species, including a comprehensive analysis of the cow genome published by a consortium of researchers in Nature Genetics.

Contact Us:

Virtue Market Research
Kumar Plaza, #103, SRPF Rd, Ramtekadi, Pune, Maharashtra 411013, India
E-mail: megha@virtuemarketresearch.com
Phone: +1-917 436 1025

Virtue Market Research is a strategic management firm helping companies to tackle most of their strategic issues and make informed decisions for their future growth. We offer syndicated reports and consulting services. Our reports are designed to provide insights on the constant flux in the global demand-supply gap of markets.

This release was published on openPR.